GlaxoSmithKline's (GSK) drug, Augmentin, is seen in the COVID-19 Intensive Care Unit (ICU) at the Centre Cardiologique du Nord private hospital in Saint-Denis, near Paris, amid the coronavirus disease pandemic in France, May 4, 2021. REUTERS/Benoit Tessier

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, speaks as U.S. President Donald Trump listens during a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, adjusts his protective face mask after speaking as President Donald Trump holds a coronavirus disease vaccine event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, listens while wearing a protective face mask as President Donald Trump holds a coronavirus disease vaccine event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

U.S. President Donald Trump passes former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, as he removes his face mask to speak during a coronavirus response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, adjusts his protective face mask after speaking as President Donald Trump holds a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

U.S. President Donald Trump looks on as former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, removes his face mask during a coronavirus response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, waits to speak as President Donald Trump holds a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, speaks as President Donald Trump listens during a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque

A tribute to the NHS is seen outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville

A general view outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville

A tribute to care workers is seen outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville

A tribute to the NHS is seen outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs

A box and vials of the drug Shingrix, made by GlaxoSmithKline Pharmaceutical, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey

A scientist studies cancer cells inside white blood cells through a microscope at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Scientists look at test tubes containing stem cells at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Scientists look at test tubes containing stem cells at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A GSK logo is seen on a flag at a GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley tours GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS